Leap Therapeutics deepened restructuring by expanding layoffs to cover 75% of staff and terminating development of its only clinical-stage asset, sirexatamab, an anti-DKK1 antibody for cancer. Following modest response rate improvements in subgroup analyses, the company cited challenging market conditions as factors driving the strategic pivot to preserve capital, explore sale or partnerships, and reduce internal expenses. Earlier plans had targeted a 50% workforce reduction, underscoring the biotech’s retreat amid sector pressures.